Clinical trial · Interventional
The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection
NCT02896413CI-TRIAL-00051606completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cancer | Malignant Uterine Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control group | Drug | — | UNRESOLVED |
| Dexmedetomidine group | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Dexmedetomidine Group
- description
- dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
- interventionNames
- Drug: Dexmedetomidine group
- type
- PLACEBO_COMPARATOR
- label
- Control Group
- description
- 0.9% saline infusion
- interventionNames
- Drug: Control group
Primary outcomes (4)
- measure
- natural killer cell cytotoxicity
- timeFrame
- 1 minute before surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ * patient scheduled for uterine cancer surgery Exclusion Criteria: * ASA physical status Ⅳ * severe hepatorenal disease * infection * metastasis to other organ * problem with communication
References
Publications (0)
Data not yet available
No reference posted for this study.